Leveraging Epigenetics to Enhance the Efficacy of Cancer-Testis Antigen: A Potential Candidate for Immunotherapy

References

• Siegel RL , MillerKD , JemalA. Cancer statistics. CA Cancer J. Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Shabir S , GillPK. Global scenario on ovarian cancer – its dynamics, relative survival, treatment, and epidemiology, 2020. Adesh Univ. J. Med. Sci. Res.2(1), 17–25 (2020).
   Google Scholar
• Torre LA , BrittonTrabert , DesantisCEet al. Ovarian cancer statistics, 2018. CA Cancer J. Clin.68, 284–296 (2018).
   PubMed Web of Science ®Google Scholar
• Du Bois A , ReussA , Pujade-LauraineEet al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer J.115(6), 1234–1244 (2009).
   Google Scholar
• ‘National Comprehensive Cancer Network – Home’. www.nccn.org/
   Google Scholar
• Winter-Roach BA , KitchenerHC , LawrieTA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst. Rev. (3), (2009).
   Web of Science ®Google Scholar
• Li Y , LiJ , WangY , ZhangYet al. Roles of cancer/testis antigens (CTAs) in breast cancer. Cancer Lett.399, 64–73 (2017).
   PubMed Web of Science ®Google Scholar
• Salmaninejad A , ZamaniMR , PourvahediMet al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol. Invest.45(7), 619–640 (2016).
   PubMed Web of Science ®Google Scholar
• Van der Bruggen P , TraversariC , ChomezPet al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Mantia-Smaldone GM , CorrB , ChuCS. Immunotherapy in ovarian cancer. Hum. Vaccin. Immunother.8(9), 1179–1191 (2012).
   PubMed Web of Science ®Google Scholar
• Sabado RL , BalanS , BhardwajN. Dendritic cell-based immunotherapy. Cell Res.27(1), 74–95 (2017).
   PubMed Web of Science ®Google Scholar
• Strickler JH , HanksBA , KhasrawM. Tumor mutational burden as a predictor of immunotherapy response: is more always better?Clin. Cancer Res.27(5), 1236–1241 (2021).
   PubMed Web of Science ®Google Scholar
• Li XF , RenP , ShenWZ , JinXet al. The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy. Am. J. Transl. Res.12(11), 7002–7019 (2020).
   PubMed Web of Science ®Google Scholar
• Elisabetta F , SandraCet al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol. Oncol.5(2), 164–182 (2011).
   PubMed Web of Science ®Google Scholar
• Kim JJ , RajagopalanK , HussainBet al. CETN1 is a cancer testis antigen with expression in prostate and pancreatic cancers. Biomark. Res.1(1), 1–7 (2013).
   PubMedGoogle Scholar
• Dang E , YangS , SongCet al. BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression. Cell Death Dis.9(8), 1–15 (2018).
   PubMedGoogle Scholar
• Anne Westbrook V , DiekmanAB , Naaby-HansenSet al. Differential nuclear localization of the cancer/testis-associated protein, SPAN-X/CTp11, in transfected cells and in 50% of human spermatozoa. Biol. Reprod.64(1), 345–358 (2001).
   PubMed Web of Science ®Google Scholar
• Salmaninejad A , ZamaniMR , PourvahediMet al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res.65(6), 2207–2215 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma A , AlbahraniM , ZhangWet al. Epigenetic activation of POTE genes in ovarian cancer. Epigenetics14(2), 185–197 (2019).
   PubMed Web of Science ®Google Scholar
• Kulkarni P , UverskyVNet al. Cancer/testis antigens: “smart” biomarkers for diagnosis and prognosis of prostate and other cancers. Int. J. Mol. Sci.18(4), 740 (2017).
   PubMed Web of Science ®Google Scholar
• Carvalho F , VettoreALet al. Cancer/testis antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin. Dev. Immunol.2012, 1–7 (2012).
   Google Scholar
• Babatunde KA , NajafiA , SalehipourPet al. Cancer/Testis genes in relation to sperm biology and function. Iran. J. Basic Med. Sci.20(9), 967 (2017).
   PubMed Web of Science ®Google Scholar
• Xie K , FuC , WangSet al. Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets. J. Ovarian Res.12(1), (2019).
   Google Scholar
• Peoples GE , AndersonBW , FiskBet al. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann. Surg. Oncol.5(8), 743–750 (1998).
   PubMed Web of Science ®Google Scholar
• Caballero OL , ChenYT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci.100(11), 2014–2021 (2009).
   PubMed Web of Science ®Google Scholar
• Zendman AJ , RuiterDJ , Van MuijenGN. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell. Physiol.194(3), 272–288 (2003).
   PubMed Web of Science ®Google Scholar
• Neumann F , WagnerC , PreussKDet al. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood106(9), 3105–3113 (2005).
   PubMed Web of Science ®Google Scholar
• Figueiredo DL , MamedeRC , SpagnoliGCet al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck33(5), 702–707 (2011).
   PubMed Web of Science ®Google Scholar
• Oi S , NatsumeA , ItoMet al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J. Neurooncol.92(1), 15–22 (2009).
   PubMed Web of Science ®Google Scholar
• Daudi S , EngKH , Mhawech-FaucegliaPet al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLOS ONE9(8), (2014).
   PubMed Web of Science ®Google Scholar
• Zhang XM , HuangY , LiZSet al. Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server. Oncol. Lett.1(6), 1097–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang Y , WangZ , ZhangJet al. Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells. Leuk. Res.33(1), 166–169 (2009).
   PubMed Web of Science ®Google Scholar
• Almanzar G , OlkhanudPB , BodogaiMet al. Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells. Clin. Cancer Res.15(6), 1954–1963 (2009).
   PubMed Web of Science ®Google Scholar
• Neesse A , GangeswaranR , LuettgesJet al. Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells. Oncogene26(11), 1533–1545 (2007).
   PubMed Web of Science ®Google Scholar
• Devor EJ , Gonzalez-BosquetJ , WarrierAet al. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. Int. J. Oncol.50(5), 1721 (2017).
   PubMed Web of Science ®Google Scholar
• Hayashi R , NagatoT , KumaiTet al. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology10(1), (2021).
   PubMed Web of Science ®Google Scholar
• Wischnewski F , FrieseO , PantelKet al. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol. Cancer Res.5(7), 749–759 (2007).
   PubMed Web of Science ®Google Scholar
• Shichijo S , YamadaA , SagawaKet al. Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine. Jpn J. Cancer Res.87(7), 751–756 (1996).
   PubMedGoogle Scholar
• Sun F , ChanE , WuZet al. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol. Cancer Ther.8(12), 3191–3202 (2009).
   PubMed Web of Science ®Google Scholar
• Chang C , LeeSO , WangRSet al. Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol. Hum. Reprod.14(2), 107–116 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu X , AsaSL , EzzatS. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res.14(7), 1984–1996 (2008).
   PubMed Web of Science ®Google Scholar
• Drakes ML , StiffPJ. Understanding dendritic cell immunotherapy in ovarian cancer. Expert Rev. Anticancer Ther.16(6), 643–652 (2016).
   PubMed Web of Science ®Google Scholar
• Hofmann M , RuschenburgI. mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Cancer Cytopathol.96(3), 187–193 (2002).
   Web of Science ®Google Scholar
• Zendman AJ , van KraatsAA , den HollanderAIet al. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int. J. Cancer97(2), 195–204 (2002).
   PubMed Web of Science ®Google Scholar
• Simpson AJ , CaballeroOL , JungbluthAet al. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer5(8), 615–625 (2005).
   PubMed Web of Science ®Google Scholar
• Dong XY , SuYR , QianXPet al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br. J. Cancer89(2), 291–297 (2003).
   PubMed Web of Science ®Google Scholar
• Xin HW , AmbeCM , HariDMet al. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut62(12), 1777–1786 (2013).
   PubMed Web of Science ®Google Scholar
• Slebos RJC , YiY , ElyKet al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin. Cancer Res.12(3), 701–709 (2006).
   PubMed Web of Science ®Google Scholar
• Loriot A , BoonT , DeSmet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int. J. Cancer105(3), 371–376 (2003).
   PubMed Web of Science ®Google Scholar
• Liggins AP , LimSH , SoilleuxEJet al. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun. a J. Acad. Cancer Immunol.10, 1–12 (2010).
   PubMedGoogle Scholar
• Moreau-Aubry A , LeGuiner S , LabarriereNet al. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J. Exp. Med.191(9), 1617–1623 (2000).
   PubMed Web of Science ®Google Scholar
• Debinski W , GiboDM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol. Med.6(5), 440 (2000).
   PubMed Web of Science ®Google Scholar
• Lin C , MakS , MeitnerPAet al. Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene285(1–2), 269–278 (2002).
   PubMed Web of Science ®Google Scholar
• Cho B , LimY , LeeDYet al. Identification and characterization of a novel cancer/testis antigen gene CAGE. Biochem. Biophys. Res. Commun.292(3), 715–726 (2002).
   PubMed Web of Science ®Google Scholar
• Lee S-Y , ObataY , YoshidaMet al. Immunomic analysis of human sarcoma. Proc. Natl Acad. Sci.100(5), 2651–2656 (2003).
   PubMed Web of Science ®Google Scholar
• Chen QW , ZhuXY , LiYYet al. Epigenetic regulation and cancer (review). Oncol. Rep.31(2), 523–532 (2014).
   PubMed Web of Science ®Google Scholar
• Wang D , WangXW , PengXCet al. CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research. Cancer Gene Ther.25(5–6), 93–105 (2018).
   PubMed Web of Science ®Google Scholar
• Liu Y , YuC , WuYet al. CD44 + fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling. J. Cell. Mol. Med.21(9), 1979–1988 (2017).
   PubMed Web of Science ®Google Scholar
• Mobasheri MB , JahanzadI , MohagheghiMAet al. Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect. Prev.31(4), 296–302 (2007).
   PubMedGoogle Scholar
• Kamerkar S , LeBleuVS , SugimotoHet al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature546(7659), 498–503 (2017).
   PubMed Web of Science ®Google Scholar
• Ruault M , vander Bruggen P , BrunM-Eet al. New BAGE (B melanoma antigen) genes mapping to the juxtacentromeric regions of human chromosomes 13 and 21 have a cancer/testis expression profile. Eur. J. Hum. Genet.10(12), 833–840 (2002).
   PubMed Web of Science ®Google Scholar
• Constantino J , GomesC , FalcaoAet al. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol. Res.65(4), 798–810 (2017).
   PubMed Web of Science ®Google Scholar
• Zhou Y , BoschML , SalgallerML. Current methods for loading dendritic cells with tumor antigen for the induction of anti-tumor immunity. J. Immunother.25(4), 289–303 (2002).
   PubMed Web of Science ®Google Scholar
• Tangjitgamol S , ManusirivithayaS , LaopaiboonMet al. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev.4(4), CD006014 (2013).
   PubMedGoogle Scholar
• Alsaab HO , SauS , AlzhraniRet al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol.8(Aug), (2017).
   PubMedGoogle Scholar
• Ribas A , DummerR , PuzanovIet al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell170(6), 1109–1119.e10 (2017).
   PubMed Web of Science ®Google Scholar
• Tammela J , UenakaA , OnoTet al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int. J. Oncol.29(4), 903–910 (2006).
   PubMed Web of Science ®Google Scholar
• Fan R , HuangW , LuoBet al. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays. Eur. J. Gynaecol. Oncol.36(3), 298–303 (2015).
   PubMed Web of Science ®Google Scholar
• Tammela J , UenakaA , OnoTet al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int. J. Oncol.29(4), 903–910 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuda T , LeisegangM , ParkJHet al. Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. Clin. Cancer Res.24(21), 5357–5367 (2018).
   PubMed Web of Science ®Google Scholar
• Woloszynska-Read A , ZhangW , YuJet al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin. Cancer Res.17(8), 2170–2180 (2011).
   PubMed Web of Science ®Google Scholar
• Renaud S , PugachevaEM , DelgadoMDet al. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res.35(21), 7372–7388 (2007).
   PubMed Web of Science ®Google Scholar
• Jones BS , LambLS , GoldmanFet al. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol.0, 254 (2014).
   Google Scholar
• Chodon T , LugadeAA , BattagliaS , OdunsiK. Emerging role and future directions of immunotherapy in advanced ovarian cancer. Hematol. Oncol. Clin. North Am.32(6), 1025 (2018).
   PubMed Web of Science ®Google Scholar
• Inoue N , HessKD , MoreadithRWet al. New gene family defined by MORC, a nuclear protein required for mouse spermatogenesis. Hum. Mol. Genet.8(7), 1201–1207 (1999).
   PubMed Web of Science ®Google Scholar
• Scanlan MJ , SimpsonAJ , OldLJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun.4 (2004).
   PubMedGoogle Scholar
• ‘NCBI Insights: NCBI to Retire the UniGene Database’. https://ncbiinsights.ncbi.nlm.nih.gov/2019/02/01/ncbi-to-retire-the-unigene-database/
   Google Scholar
• Scanlan MJ , AltorkiNK , GureAOet al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett.150(2), 155–164 (2000).
   PubMed Web of Science ®Google Scholar
• Dong XY , SuYR , QianXPet al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br. J. Cancer89(2), 291–297 (2003).
   PubMed Web of Science ®Google Scholar
• Atanackovic D , ArfstenJ , CaoYet al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood109(3), 1103–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Kratzschmar J , HaendlerB , EberspaecherUet al. The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3. Eur. J. Biochem.236(3), 827–836 (1996).
   PubMedGoogle Scholar
• Loriot A , BoonT , DeSmet C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int. J. Cancer105(3), 371–376 (2003).
   PubMed Web of Science ®Google Scholar
• Sulek J , GoliadzeE , ZhouSet al. The expression of cancer/testis antigens in kidney and bladder malignancies. Arch. Med.8(2), (2016).
   Google Scholar
• Taguchi A , TaylorAD , RodriguezJet al. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. Cancer Res.74(17), 4694–4705 (2014).
   PubMed Web of Science ®Google Scholar
• Scanlan MJ , GordonCM , WilliamsonBet al. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int. J. Cancer98(4), 485–492 (2002).
   PubMed Web of Science ®Google Scholar
• Shan J , YuanL , XiaoQet al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells 1. Cancer Res.62, 290–294 (2002).
   PubMed Web of Science ®Google Scholar
• Eichmüller S , UsenerD , DummerRet al. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc. Natl Acad. Sci. USA98(2), 629 (2001).
   PubMed Web of Science ®Google Scholar
• De Jong A , BuchliR , RobbinsD. Characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Lett.186(2), 201–209 (2002).
   PubMed Web of Science ®Google Scholar
• De Wit NJ , WeidleUH , RuiterDJet al. Expression profiling of MMA-1a and splice variant MMA-1b: new cancer/testis antigens identified in human melanoma. Int. J. Cancer98(4), 547–553 (2002).
   PubMed Web of Science ®Google Scholar
• Takimoto M , WeiG , Dosaka-AkitaHet al. Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br. J. Cancer86(11), 1757–1762 (2002).
   PubMed Web of Science ®Google Scholar
• Madsen B , TarsounasM , BurchellJMet al. PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localization pattern during meiosis. Chromosoma112(3), 124–132 (2003).
   PubMed Web of Science ®Google Scholar
• Koslowski M , ZlemO , ReciTet al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. 1, 2 (2002).
   Google Scholar
• Yamada R , TakahashiA , TorigoeTet al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens81(6), 428–434 (2013).
   PubMedGoogle Scholar
• Feichtinger J , LarcombeL , McFarlaneRJ. Meta-analysis of expression of l(3)MBT tumor-associated germline genes supports the model that a soma-to-germline transition is a hallmark of human cancers. Int. J. Cancer134(10), 2359–2365 (2014).
   PubMed Web of Science ®Google Scholar
• Gibbs ZA , WhitehurstAW. Emerging contributions of cancer/testis antigens to neoplastic behaviors 1. Trends in Cancer4(10), 710–712 (2018).
   Google Scholar
• Yao J , CaballeroOL , YungWKAet al. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol. Res.2(4), 371 (2014).
   PubMed Web of Science ®Google Scholar
• Sigalotti L , CoralS , AltomonteMet al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br. J. Cancer86(6), 979 (2002).
   PubMed Web of Science ®Google Scholar
• Li Y , SunL , ZhangYet al. The histone modifications governing TFF1 transcription mediated by estrogen receptor. J. Biol. Chem.286(16), 13925–13936 (2011).
   PubMed Web of Science ®Google Scholar
• Jit BP , QaziS , AryaR , SrivastavaA , GuptaN , SharmaA. An immune epigenetic insight to COVID-19 infection. Epigenomics13(06), 465–480 (2021).
   PubMed Web of Science ®Google Scholar
• Kundu S , RayMD , SharmaA. Interplay between genome organization and epigenomic alterations of pericentromeric DNA in cancer. J. Genet. Genomics48(3), 184–197 (2021).
   PubMed Web of Science ®Google Scholar
• Li B , CareyM , WorkmanJL. The role of chromatin during transcription. Cell128(4), 707–719 (2007).
   PubMed Web of Science ®Google Scholar
• Tachibana M , SugimotoK , NozakiMet al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev.16(14), 1779–1791 (2002).
   PubMed Web of Science ®Google Scholar
• Strahl BD , AllisCD. The language of covalent histone modifications. Nature403(6765), 41–45 (2000).
   PubMed Web of Science ®Google Scholar
• De Smet C , LurquinC , LethéBet al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol.19(11), 7327–7335 (1999).
   PubMed Web of Science ®Google Scholar
• Link PA , GangisettyO , JamesSRet al. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol. Cancer Res.7(6), 851–862 (2009).
   PubMed Web of Science ®Google Scholar
• Janssen BL , vande Locht LT , FourkourAet al. Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique. Melanoma Res.9(3), 213–222 (1999).
   PubMed Web of Science ®Google Scholar
• Akers SN , OdunsiK , KarpfAR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol.6(5), 717–732 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen P , Bar-SelaG , SunLet al. BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression. Mol. Cell. Biol.28(21), 6720–6729 (2008).
   PubMed Web of Science ®Google Scholar
• Roman-Gomez J , Jimenez-VelascoA , AgirreXet al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica92(2), 153–162 (2007).
   PubMed Web of Science ®Google Scholar
• Link PA , ZhangW , OdunsiKet al. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Cancer Immun.13(1), (2013).
   PubMedGoogle Scholar
• Heinrich MC , BlankeCD , DrukerBJet al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol.20(6), 1692–1703 (2002).
   PubMed Web of Science ®Google Scholar
• Kondo T , ZhuX , AsaSLet al. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res.13(16), 4713–4720 (2007).
   PubMed Web of Science ®Google Scholar
• Cheema Z , Hari-GuptaY , KitaG-Xet al. Expression of the cancer-testis antigen BORIS correlates with prostate cancer. Prostate74(2), 164–176 (2014).
   PubMed Web of Science ®Google Scholar
• Jagadish N , RanaR , SelviRet al. Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem. J.389(Pt 1), 73 (2005).
   PubMedGoogle Scholar
• Nguyen P , CuiH , BishtKSet al. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region. Cancer Res.68(14), 5546–5551 (2008).
   PubMed Web of Science ®Google Scholar
• Garg M , ChaurasiyaD , RanaRet al. Sperm-associated antigen 9, a novel cancer-testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin. Cancer Res.13(5), 1421–1428 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y , WangZ , ZhangJet al. Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells. Leuk. Res.33(1), 166 (2009).
   PubMed Web of Science ®Google Scholar
• Saito K , NishidaKM , MoriTet al. Specific association of Piwi with rasiRNAs derived from retrotransposon and heterochromatic regions in the Drosophila genome. Genes Dev.20(16), 2214 (2006).
   PubMed Web of Science ®Google Scholar
• Katahira J , YonedaY. Nucleocytoplasmic transport of microRNAs and related small RNAs. Traffic12(11), 1468–1474 (2011).
   PubMed Web of Science ®Google Scholar
• Saxe JP , LinH. Small noncoding RNAs in the germline. Cold Spring Harb. Perspect. Biol.3(9), 1–16 (2011).
   Web of Science ®Google Scholar
• Caballero OL , ChenY-T. Cancer/ testis (CT) antigens: potential targets forimmunotherapy. Innate Immune Regulations and Cancer Immune therapy.348–369 (2012).
   Google Scholar
• Lim SL , RicciardelliC , OehlerMKet al. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLOS ONE9(6), e99687 (2014).
   PubMed Web of Science ®Google Scholar
• Taherian-Esfahani Z , Abedin-DoA , NikpayamEet al. Cancer-testis antigens: a novel group of tumor biomarkers in ovarian cancers. Iran. J. Cancer Prev.9(6), (2016).
   PubMedGoogle Scholar
• Tchabo NE , Mhawech-FaucegliaP , CaballeroOLet al. Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer. Cancer Immun. A. J. Acad. Cancer Immunol.9 (2009).
   Google Scholar
• Jagadish N , FatimaR , SharmaAet al. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. Tumour Biol.40(5), (2018).
   PubMedGoogle Scholar
• Garg M , ChaurasiyaD , RanaRet al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clinical Cancer Res.13(5), 1421–1428(2007).
   PubMed Web of Science ®Google Scholar
• Whitehurst AW , XieY , PurintonSCet al. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res.70(19), 7652–7661 (2010).
   PubMed Web of Science ®Google Scholar
• Liu Y , DouM , SongXet al. The emerging role of the piRNA/piwi complex in cancer. Mol. Cancer18(1), 1–15 (2019).
   PubMed Web of Science ®Google Scholar
• Odunsi K , JungbluthAA , StockertEet al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer 1. Cancer Res.63, 6076–6083 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Y . Cancer immunity. 4, 11 (2004).
   Google Scholar
• Xie K , FuC , WangSet al. Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets. J. Ovarian Res.12(1), 1–13 (2019).
   PubMedGoogle Scholar
• Mobasheri MB , ModarressiMH , ShabaniMet al. Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). Leuk. Res.30(7), 883–889 (2006).
   PubMed Web of Science ®Google Scholar
• Martelange V , DeSmet C , DePlaen Eet al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res.60, 3848–3855 (2000).
   PubMed Web of Science ®Google Scholar
• Tanaka R , OnoT , SatoSet al. Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity. Microbiol. Immunol.48(4), 339–345 (2004).
   PubMed Web of Science ®Google Scholar
• Oram SW , LiuXX , LeeTLet al. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer6(1), 1–15 (2006).
   PubMedGoogle Scholar
• Sharma S , QianF , KeitzBet al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol. Oncol.99(1), 183–188 (2005).
   PubMed Web of Science ®Google Scholar
• Van Baren N , BonnetMC , DrénoBet al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol.23(35), 9008–9021 (2005).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA , TerabeM , WoodLV. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin. Oncol.39(3), 348–357 (2012).
   PubMed Web of Science ®Google Scholar
• Høgdall EV , ChristensenL , KjaerSKet al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer98(1), 66–73 (2003).
   PubMed Web of Science ®Google Scholar
• Karyampudi L , FormicolaC , ErskineCLet al. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin. Cancer Res.16(3), 825–834 (2010).
   PubMed Web of Science ®Google Scholar
• Brown Jones M , NeuperC , ClaytonAet al. Rationale for folate receptor alpha targeted therapy in ‘high risk’ endometrial carcinomas. Int. J. Cancer123(7), 1699–1703 (2008).
   PubMed Web of Science ®Google Scholar
• Elnakat H , RatnamM. Role of folate receptor genes in reproduction and related cancers. Front. Biosci.11(1 P.447–888), 506–519 (2006).
   PubMedGoogle Scholar
• Taherian-Esfahani Z , Abedin-DoA , NikpayamEet al. Cancer-testis antigens: a novel group of tumor biomarkers in ovarian cancers. Iran. J. Cancer Prev.9(6), (2016).
   PubMedGoogle Scholar
• Schlienger K , ChuCS , WooEYet al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res.9(4), 1517–1527 (2003).
   PubMed Web of Science ®Google Scholar
• James FR , Jiminez-LinanM , AlsopJ et al. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer17(1), 1–7 (2017).
   PubMedGoogle Scholar
• Hwang C , LeeSJ , LeeJH et al. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. Oncol. Lett.17(5), 4557–4565 (2019).
   PubMed Web of Science ®Google Scholar
• Toker A , NguyenLT , StoneSCet al. Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma. Clin. Cancer Res.24(22), 5685–5696 (2018).
   PubMed Web of Science ®Google Scholar
• Cannistra SA . Cancer of the ovary. N. Engl. J. Med.351(24), 2519–2529 (2004).
   PubMed Web of Science ®Google Scholar
• Adams SF , LevineDA , CadungogMGet al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer115(13), 2891–2902 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke B , TinkerAV , LeeCHet al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol.22(3), 393–402 (2009).
   PubMed Web of Science ®Google Scholar
• Adams SF , LevineDA , CadungogMGet al. Intraepithelial T cells and tumor proliferation. Cancer115(13), 2891–2902 (2009).
   PubMed Web of Science ®Google Scholar
• Woo EY , YehH , ChuCSet al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol.168(9), 4272–4276 (2002).
   PubMed Web of Science ®Google Scholar
• Hwang WT , AdamsSF , TahirovicEet al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol.124(2), 192–198 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ZhangY , ZhangL. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy. J. Cancer Res. Clin. Oncol.145(2), 281–291 (2019).
   PubMed Web of Science ®Google Scholar
• Robbins PF , MorganRA , FeldmanSAet al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol.29(7), 917–924 (2011).
   PubMed Web of Science ®Google Scholar
• Markert S , LassmannS , GabrielBet al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res.28(6A), 3567–3572 (2008).
   PubMed Web of Science ®Google Scholar
• Verri E , GuglielminiP , PuntoniMet al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology68(2–3), 154–161 (2005).
   PubMed Web of Science ®Google Scholar
• Lanitis E , SmithJB , DangajDet al. A human ErbB2-specific T-Cell receptor confers potent anti-tumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum. Gene Ther.25(8), 730 (2014).
   PubMed Web of Science ®Google Scholar
• Kershaw MH , WestwoodJA , ParkerLLet al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res.12(20 Pt 1), 6106–6115 (2006).
   PubMed Web of Science ®Google Scholar
• Siu MKY , KongDSH , ChanHYet al. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLOS ONE7(11), e47201 (2012).
   PubMed Web of Science ®Google Scholar
• Kandalaft LE , PowellDJJr , CoukosG. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J. Transl. Med.10(1), 1–10 (2012).
   PubMedGoogle Scholar
• Schoutrop E , El-SerafiI , PoiretTet al. Mesothelin-Specific CAR T cells target ovarian cancer. Cancer Res.81(11), 3022–3055 (2021).
   PubMed Web of Science ®Google Scholar
• Liu JF , MooreKN , BirrerMJet al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.27(11), 2124–2130 (2016).
   PubMed Web of Science ®Google Scholar
• Chekmasova AA , RaoTD , NikhaminYet al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res.16(14), 3594–3606 (2010).
   PubMed Web of Science ®Google Scholar
• Koneru M , O’CearbhaillR , PendharkarSet al. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med.13(1), 1–11 (2015).
   PubMedGoogle Scholar
• Akahori Y , WangL , YoneyamaMet al. Anti-tumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood132(11), 1134–1145 (2018).
   PubMed Web of Science ®Google Scholar
• Banchereau J , SteinmanRM. Dendritic cells and the control of immunity. Nature392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Coosemans A , BaertT , VergoteI. A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?Facts Views Vis. ObGyn.7(1), 73 (2015).
   PubMed Web of Science ®Google Scholar
• Hsu FJ , BenikeC , FagnoniFet al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med.2(1), 52–58 (1996).
   PubMed Web of Science ®Google Scholar
• Nestle FO , AlijagicS , GillietMet al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med.4(3), 328–332 (1998).
   PubMed Web of Science ®Google Scholar
• Whiteside TL , FerrisRL , SzczepanskiMet al. Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma: promise vs reality. Head Neck38(Suppl. 1), E494 (2016).
   PubMedGoogle Scholar
• Okada H , KalinskiP , UedaRet al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol.29(3), 330–336 (2011).
   PubMed Web of Science ®Google Scholar
• Xin HW , HariDM , MullinaxJEet al. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells30(4), 591–598 (2012).
   PubMed Web of Science ®Google Scholar
• Wei X , ChenF , XinKet al. Cancer-testis antigen peptide vaccine for cancer immunotherapy: progress and prospects. Transl. Oncol.12(5), 733–738 (2019).
   PubMed Web of Science ®Google Scholar
• ‘Home - ClinicalTrials.gov’. https://clinicaltrials.gov/
   Google Scholar
• Cruz CR , GerdemannU , LeenAMet al. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin. Cancer Res.17(22), 7058–7066 (2011).
   PubMed Web of Science ®Google Scholar
• Zajac P , Schultz-ThaterE , TornilloLet al. MAGE-A antigens and cancer immunotherapy. Front. Med.0(MAR), 18 (2017).
   Google Scholar
• Lattanzi M , HanJ , MoranUet al. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis. J. Immunother. Cancer6(1), 1–10 (2018).
   PubMedGoogle Scholar
• Zhang Y , ZhangY , ZhangL. Expression of cancer–testis antigens in esophageal cancer and their progress in immunotherapy. J. Cancer Res. Clin. Oncol.145(2), 281–291 (2019).
   PubMed Web of Science ®Google Scholar
• Cintolo JA , DattaJ , MathewSJ , CzernieckiBJ. Dendritic cell-based vaccines: barriers and opportunities. Future Oncol.8(10), 1273–1299 (2012).
   PubMed Web of Science ®Google Scholar
• Gök M , ÖzceritAT. Prediction of MHC class I binding peptides with a new feature encoding technique. Cell. Immunol.275(1–2), 1–4 (2012).
   PubMed Web of Science ®Google Scholar
• Kortleve D , CoelhoRML , HammerD , DebetsR. Cancer germline antigens and tumor-agnostic CD8+ T cell evasion. Trends Immunol. (2022). ( In Press).
   PubMed Web of Science ®Google Scholar
• June CH , O’ConnorRS , KawalekarOU , GhassemiS , MiloneMC. CAR T cell immunotherapy for human cancer. Science359(6382), 1361–1365 (2018).
   PubMed Web of Science ®Google Scholar
• Sadelain M , BrentjensR , RivièreI. The basic principles of chimeric antigen receptor design. Cancer Discov.3(4), 388–398 (2013).
   PubMed Web of Science ®Google Scholar